InvivoGen Reviews

Read the Review
Immune Checkpoint Blockade: InestimAble Advances
Over the last decade, the understanding of key steps in the regulation of T cell responses has led to the groundbreaking development of immune checkpoint blocking monoclonal antibodies (mAbs) to fight cancer. The first FDA-approved mAbs have provided unprecedented remissions in melanoma and non-small cell lung cancer, although with considerable variation in response rates (10% to 90%) and significant toxicity1,2. This revolution in cancer therapy is now the basis for new IC-based curative strategies.
Previous issues
Pages
- « first
- ‹ previous
- 1
- 2
- 3